Health Economics›Pancreatic cancer›Adjuvant therapy

Adjuvant therapy

Pancreatic cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Gemcitabine/Fluorouracil and RT Variant #01	—	R 11 569	77d	—	20.5 mo	3	R 21 602 PFS proxy	1
Capecitabine and Gemcitabine Variant #01	—	R 6 309	21d	—	29.8 mo	6	R 37 856 PFS proxy	2
FULV Variant #29	—	R 3 601	14d	—	23.0 mo	2	R 7 201 PFS proxy	3
mFOLFIRINOX Variant #04	—	R 3 444	14d	—	53.5 mo	2	R 6 887 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	25.5 mo	7	R 11 705 PFS proxy	7
Fluorouracil and RT Variant #01	—	R 809	42d	—	17.1 mo	1	R 809 PFS proxy	1
S-1 monotherapy Variant #01 Partial	—	—	21d	—	—	2	—	1
Observation Partial	—	—	—	—	18.4 mo	—	—	2
Fluorouracil/Fluorouracil and RT Partial	—	—	—	—	—	—	—	—

9 of 9 regimens shown